What We're Reading: Page 328
Industry reads hand-picked by our editors
Sep 14, 2016
-
Financial Times
Takeda earmarks $15bn for US pharmaceutical acquisitions
-
Forbes
How GlaxoSmithKline took its medicine
-
The Street
Sarepta drug critic departs FDA, raising hope for approval
-
Wall Street Journal
EpiPen maker dispenses outsize pay
-
Regulatory Focus
FDA to hold one advisory committee for each initial biosimilar
Sep 13, 2016
-
Stat
Ego, ambition, and turmoil: Inside one of biotech’s most secretive startups
-
Wall Street Journal
High cost of new hepatitis C drugs strains prison budgets, locks many out of cure
-
Forbes
Celgene data offer a Rorschach test to Wall Street
-
Triangle Business Journal
IMS Health to raise $1.5B in connection with Quintiles buy
Sep 12, 2016
Sep 09, 2016
-
Bloomberg
Bayer said to explore sale of $1.1 billion dermatology business
-
Stat
Bold claim of multiple sclerosis gene discovery comes under withering attack
-
New York Times
A push to lower drug prices that hit insurers and employers the hardest
-
Reuters
Statins' benefits understated and harms exaggerated, scientists warn
Sep 08, 2016
Sep 07, 2016
-
Xconomy
With new name and $47M, Proclara begins first big Alzheimer's test
-
The Street
Retrophin (with help from Martin Shkreli) advances drug for rare kidney disease
-
Stat
Doctors Without Borders urges Gilead to rethink its hepatitis C strategy in Ukraine
-
Endpoints
Moderna blueprints $100M facility, plans to double the pipeline after a $474M megaround
Sep 06, 2016
-
Vanity Fair
How Elizabeth Holmes's house of cards came tumbling down
-
Bloomberg
Drug industry group starts ad campaign to push back on pricing
-
Wall Street Journal
New drugs for ovarian cancer patients
-
The Hill
EpiPen maker feels heat from Congress
-
Reuters
Danaher to buy Cepheid in $4 billion deal to expand in diagnostics
Previous
